#China #Chengdu #Kelun-Biotech #Pembrolizumab #sacituzumab tirumotecan

New Approval for Sacituzumab Tirumotecan in PD-L1-Negative NSCLC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. recently announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has accepted a new indication application for sacituzumab tirumotecan (sac-TMT), a TROP2-directed antibody-drug conjugate (ADC). This application has particular significance as it aims to combine sac-TMT with MSD’s pembrolizumab (KEYTRUDA) as a first-line treatment for patients battling advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors exhibit PD-L1 tumor proportion scores (TPS) of less than 1% and are both EGFR and ALK negative.

This is the seventh indication application for sac-TMT and marks an important advancement in the treatment of a patient population that faces limited options. The approval is based on robust findings from the Phase III OptiTROP-Lung06 study, which reported that the combination of sac-TMT and pembrolizumab effectively improved progression-free survival compared to traditional chemotherapy regimens.

Key Study Insights

The OptiTROP-Lung06 study set itself apart as the world’s first Phase III clinical trial that successfully demonstrated the efficacy of an ADC combined with an immune checkpoint inhibitor for first-line treatment in driver gene-negative and PD-L1-negative NSCLC. Results indicated that the combination not only met but exceeded expectations, showing statistically significant and clinically meaningful improvements in progression-free survival (PFS).

During a prespecified interim analysis, it was concluded that sac-TMT plus pembrolizumab had a notably favorable PFS compared with the pembrolizumab plus standard chemotherapy treatment. Additionally, a positive trend concerning overall survival (OS) was observed, which further cements the promise of this novel treatment regimen.

A New Era for NSCLC Treatment

Given the high unmet medical need among patients with PD-L1-negative tumors, this application is critically positioned to reshape the treatment landscape for NSCLC. Dr. Michael Ge, CEO of Kelun-Biotech, emphasized the importance of this advancement, stating that the progress highlights not only the potential of this combination therapy but also its ability to enhance treatment efficacy across a broader range of lung cancer patients.

“The acceptance for review signifies a hopeful future for NSCLC patients who lack viable treatment alternatives,” Dr. Ge noted.

Background on Sacituzumab Tirumotecan

Sac-TMT is a groundbreaking ADC that targets TROP2, primarily developed for treating solid tumors such as NSCLC, breast cancer, and several others. The drug's innovative design features a bivalent linker that maximizes drug delivery to cancer cells, allowing a tailored approach to attack tumors while minimizing damage to surrounding healthy tissues. It delivers a potent topoisomerase I inhibitor that disrupts cancer cell division and promotes apoptosis.

With four indications already approved in China, including those for various stages of lung cancer and breast cancer, sac-TMT is positioned as a vital addition to the arsenal against solid tumors, particularly in patients who have exhausted previous treatment options.

Future Directions

As Kelun-Biotech and its strategic partner MSD move forward with their global clinical development plans, they have initiated nine registrational trials within China and 18 global Phase III studies targeting various cancers using sac-TMT in combination with pembrolizumab and other agents. These actions demonstrate a clear commitment to advancing treatment alternatives for patients struggling with cancers typically considered difficult to treat.

In conclusion, the acceptance of this new indication application is not merely a regulatory milestone; it represents a clarification of hope for patients grappling with challenging cancer diagnoses, setting the stage for broader adoption of advanced treatment regimens involving innovative therapies such as sacituzumab tirumotecan.